Search results
Results From The WOW.Com Content Network
The Vaughan Williams classification [1] was introduced in 1970 by Miles Vaughan Williams. [2] Vaughan Williams was a pharmacology tutor at Hertford College, Oxford. One of his students, Bramah N. Singh, [3] contributed to the development of the classification system. The system is therefore sometimes known as the Singh-Vaughan Williams ...
Miles Vaughan Williams. (Edward) Miles Vaughan Williams (8 August 1918 – 31 August 2016) was a British cardiac pharmacologist and academic. He is best known for the Vaughan Williams classification of antidysrhythmic drugs. [1] From 1955 to 1985, he was a Fellow of Hertford College, Oxford, and its Tutor in medicine. [2]
Sodium channel blockers are used in the treatment of cardiac arrhythmia. They are classified as "Type I" in the Vaughan Williams classification. Class I antiarrhythmic agents interfere with the (Na +) channel. Class I agents are grouped by their effect on the Na + channel, and by their effect on cardiac action potentials.
Procainamide (PCA) is a medication of the antiarrhythmic class used for the treatment of cardiac arrhythmias. It is a sodium channel blocker of cardiomyocytes; thus it is classified by the Vaughan Williams classification system as class Ia.
In 1969, Singh was awarded a Nuffield travelling fellowship and moved to Oxford to work with Miles Vaughan Williams. There, he worked on the anti-arrhythmic properties of drugs including amiodarone. Such work helped to refine the characteristics of Class III compounds in the developing Vaughan Williams classification.
These agents are commonly classified by the type of ion they manipulate and named the Vaughan Williams classification: Class I — Sodium channel blockers. Class Ia — Fast sodium channels (quinidine, ajmaline, procainamide, disopyramide) Class Ib — Sodium channels (lidocaine, phenytoin, mexiletine, tocainide)
Proarrhythmia. Proarrhythmia is a new or more frequent occurrence of pre-existing arrhythmias, paradoxically precipitated by antiarrhythmic therapy, which means it is a side effect associated with the administration of some existing antiarrhythmic drugs, as well as drugs for other indications. In other words, it is a tendency of antiarrhythmic ...
He became interested in experimental cardiac arrhythmia and antiarrhythmic drugs, area rather unexplored at that time. Worked with Dr. E. M. Vaughan Williams comparing the electrophysiological actions of different antiarrhythmic drugs. The result of their cooperation formed the basis of 'Vaughan Williams Classification' of antiarrhythmic drugs.